10-Q: Milestone Pharma Secures Funding, Eyes Q4 Etripamil Approval

Milestone Pharmaceuticals reports increased losses but strengthens liquidity with a new $48.7 million public offering and an extended royalty agreement, as its lead drug etripamil nears FDA approval with a December 13, 2025 PDUFA date.

Summary

• Milestone Pharmaceuticals reported a net loss of $33.7 million for the six months ended June 30, 2025, a significant increase from $19.7 million in the same period of 2024.
• Operating expenses rose by 64.1% to $33.1 million for the six months ended June 30, 2025, driven primarily by a 230.4% increase in commercial expenses to $15.5 million in preparation for the CARDAMYST launch.
• The company had cash, cash equivalents, and short-term investments totaling $43.4 million as of June 30, 2025.
• The FDA accepted Milestone's response to the Complete Response Letter (CRL) for CARDAMYST (etripamil) nasal spray for PSVT, setting a new PDUFA target date of December 13, 2025.
• Milestone completed an underwritten public offering on July 11, 2025, raising approximately $48.7 million in net proceeds through the issuance of common shares and accompanying Series A and Series B warrants.
• The Royalty Purchase Agreement with RTW Investments LP was amended, extending the marketing approval deadline for etripamil from September 30, 2025, to December 31, 2025, for a potential $75.0 million payment upon FDA approval.
• Clinical data for etripamil in PSVT (NODE-303 and RAPID studies) showed consistent efficacy, with 60.0% conversion by 30 minutes in NODE-303 and 64.3% conversion by 30 minutes in RAPID, and a median time to conversion of 17 minutes.
• Positive Phase 2 data for etripamil in AFib-RVR demonstrated a significant ventricular rate reduction of 29.91 bpm compared to placebo (p<0.0001) and improved patient satisfaction.
• Enrollment for the Phase 3 AFib-RVR study is delayed due to the CRL received for the PSVT NDA.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the company continues to incur significant losses and has delayed a key clinical trial, the successful capital raise and the FDA's acceptance of the CRL response with a new PDUFA date for its lead product are strong positive catalysts that de-risk the near-term financial and regulatory outlook, providing a clear path to potential commercialization.

Positives

• The FDA accepted the company's response to the Complete Response Letter (CRL) for CARDAMYST (etripamil) nasal spray, establishing a new PDUFA target date of December 13, 2025, which provides a clear regulatory path forward.
• Successfully completed an underwritten public offering on July 11, 2025, raising approximately $48.7 million in net proceeds, significantly strengthening the company's cash position and extending its operational runway for at least 12 months.
• The Royalty Purchase Agreement with RTW Investments LP was amended to extend the marketing approval deadline to December 31, 2025, maintaining the potential for a $75.0 million payment upon FDA approval.
• Clinical trials for etripamil in PSVT (NODE-303 and RAPID) consistently demonstrated positive efficacy and safety profiles, with high conversion rates and reduced need for emergency department visits.
• Positive Phase 2 data for etripamil in AFib-RVR (ReVeRA study) showed statistically significant and clinically meaningful reductions in ventricular rate and improved patient symptom relief, supporting further development for this indication.
• The company's licensing partner, Corxel, reported positive Phase 3 data for etripamil in PSVT in China, further validating the drug's efficacy and safety globally.

Negatives

• Net loss significantly increased to $33.7 million for the six months ended June 30, 2025, compared to $19.7 million in the prior year period, indicating a higher cash burn rate.
• Operating expenses increased substantially, particularly commercial expenses, as the company prepares for a product launch that is contingent on regulatory approval.
• The initial Complete Response Letter (CRL) from the FDA in March 2025 caused a temporary pause in ramping up operational expenditures related to the etripamil launch.
• Enrollment for the Phase 3 AFib-RVR study is delayed due to the prior CRL for the PSVT NDA, pushing back the development timeline for this indication.
• The company continues to incur significant operating losses and has an accumulated deficit of $401.3 million as of June 30, 2025, highlighting its pre-revenue stage and reliance on external funding.

Risks

• Future success is substantially dependent on obtaining regulatory approval for etripamil, which is unpredictable and may require additional costly clinical trials or result in approval for a limited indication.
• Disruptions at the FDA and other government agencies (e.g., layoffs, funding shortages, policy changes) could delay product review and approval times.
• International trade policies, including tariffs, sanctions, and trade barriers, may adversely affect the business, particularly due to reliance on third-party suppliers for active pharmaceutical ingredients (APIs) from China.
• Healthcare legislative reforms (e.g., PPACA, OBBBA, IRA, drug pricing scrutiny, state importation programs) could limit reimbursement amounts, reduce demand, or increase pricing pressures for approved products.
• Future changes to tax laws, such as the OBBBA's impact on R&E expenditures, could increase tax liability and adversely affect financial performance.
• The company relies on third parties for manufacturing, which introduces risks related to supply delays, compliance with regulations, and quality control.
• The recent U.S. Supreme Court decision in Loper Bright could lead to additional legal challenges to current regulations and guidance issued by federal agencies, including the FDA, creating regulatory uncertainty.

Future Outlook

The company anticipates continuing to incur significant losses for the foreseeable future as it focuses on completing development activities, obtaining regulatory approval, and preparing for potential commercialization of etripamil for PSVT and AFib-RVR. Expenses are expected to increase with marketing approval efforts, establishment of sales and marketing capabilities, and continued development of etripamil for additional indications. The company expects its existing cash, cash equivalents, short-term investments, and proceeds from the recent July 2025 offering to fund operations for at least the next 12 months.

Management Comments

• Management expects to be able to support operations for at least the next 12 months from the date of issuance of these unaudited interim condensed consolidated financial statements, with the inclusion of net proceeds from the July 11, 2025 offering.
• Milestone temporarily paused the ramping up of operational expenditures related to launch [due to the CRL] and has focused on compliantly engaging healthcare providers and payers in profiling and disease state discussions with the goal of optimizing the launch plan for CARDAMYST.
• Milestone continues to maintain the capability of launching quickly following the potential approval of CARDAMYST by the FDA.

Industry Context

The filing highlights a significant unmet need in the treatment of paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR), conditions affecting millions of Americans and incurring billions in healthcare costs annually. Current treatments for PSVT are primarily intravenous and administered in emergency settings, while AFib-RVR often leads to ED visits due to delayed onset of oral medications. Etripamil, as a rapid-onset nasal spray, aims to provide a patient-administered, at-home treatment option, potentially shifting care out of costly emergency departments and addressing a long-standing lack of pharmaceutical innovation in these areas. The increasing use of wearable ECG technology is expected to further increase diagnosed prevalence of PSVT, expanding the addressable market.

Comparison to Industry Standards

• Etripamil's median time to conversion of 17.2 minutes in the RAPID trial compares favorably to the typical onset of action for existing intravenous treatments like adenosine, verapamil, and diltiazem, which require medical supervision.
• The observed reduction in additional medical interventions (43% less) and emergency department visits (39% fewer) in combined PSVT studies (RAPID and NODE-301) suggests a significant improvement in patient self-management and potential cost savings compared to current standards of care that often necessitate ED visits.
• For AFib-RVR, etripamil's rapid ventricular rate reduction (29.91 bpm) and improved symptom relief in the ReVeRA study offer a potential advantage over acute oral rate control drugs, which have a 30to 90-minute delayed onset of action and often fail to prevent ED visits.
• The company's strategy to enable patient self-treatment at home for PSVT and AFib-RVR aligns with broader healthcare trends towards patient-centered care and reducing burdensome and costly emergency department utilization, a significant differentiator from existing hospital-administered therapies.

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings, and not aware of any pending or threatened legal proceeding that could have an adverse effect on the business, operating results, or financial condition.

Related Party Transactions

• Entered into a note purchase agreement with RTW Investments LP and certain affiliates on March 29, 2023, for $50.0 million principal amount of 6.0% Convertible Senior Notes due 2029.
• Entered into a license and collaboration agreement with Corxel Pharmaceuticals (an entity affiliated with RTW Investments, LP) on May 15, 2021, granting exclusive development and commercialization rights for etripamil in Greater China.
• Entered into a Royalty Purchase Agreement with RTW Investments LP on March 27, 2023, amended on July 10, 2025, for RTW to purchase royalty rights on etripamil net product sales in the US for $75.0 million upon FDA approval.

Stakeholder Impact

• **Shareholders**: Potential for significant dilution from the recent public offering and future equity raises. However, the capital raise provides crucial funding for operations and commercialization efforts, potentially increasing long-term value if etripamil is approved and successfully launched. The PDUFA date is a major catalyst for share price movement.
• **Employees**: Continued investment in R&D and commercial activities, along with share-based compensation plans, indicates ongoing commitment to personnel. The delay in the AFib-RVR study might affect some R&D timelines.
• **Customers (Patients)**: Potential for a novel, self-administered treatment for PSVT and AFib-RVR, offering greater control over their conditions and potentially reducing the need for emergency department visits.
• **Healthcare Providers**: Etripamil could provide a new, convenient treatment option for PSVT and AFib-RVR, addressing a current lack of effective at-home solutions and potentially reducing the burden on emergency services.
• **Payors**: The potential for etripamil to reduce emergency department visits and hospital admissions for PSVT and AFib-RVR could lead to significant healthcare cost savings.

Next Steps

• Awaiting FDA decision on CARDAMYST (etripamil) nasal spray for PSVT by the new PDUFA target date of December 13, 2025.
• Preparing for potential commercial launch of CARDAMYST in the United States following FDA approval.
• Continuing to engage healthcare providers and payers to optimize the launch plan for CARDAMYST.
• Initiating the Phase 3 study for etripamil in AFib-RVR once the PSVT NDA situation is resolved, with a focus on a self-administered, repeat-dose regimen in a medically unmonitored setting.
• Potentially seeking marketing approvals for etripamil for other cardiovascular indications.
• Building a portfolio of product candidates through development, acquisition, or in-licensing.
• Maintaining, protecting, and expanding the intellectual property portfolio for etripamil and future product candidates.

Key Dates

Recommendation

The company has successfully navigated a significant regulatory hurdle by getting its CRL response accepted and securing a new PDUFA date of December 13, 2025, for its lead product, etripamil. This provides a clear, near-term catalyst for potential FDA approval. Furthermore, the recent $48.7 million capital raise, combined with the potential $75.0 million from the royalty agreement upon approval, significantly strengthens the company's financial position and extends its cash runway for at least 12 months, mitigating immediate liquidity concerns. Positive clinical data for etripamil in both PSVT and AFib-RVR supports its therapeutic potential. While the company is pre-revenue and incurring losses, the de-risking of the regulatory pathway and improved financial stability make it an attractive 'buy' for investors willing to take on the inherent risks of a biotech company approaching commercialization.

Keywords

Etripamil, CARDAMYST, PSVT, AFib-RVR, Nasal Spray, Cardiovascular Medicine, FDA Approval, PDUFA, Clinical Trials, Biopharmaceutical, SEC Filing, 10-Q, Public Offering, Warrants, Royalty Agreement